Tina Marriott Larson net worth and biography

Tina Larson Biography and Net Worth

Tina Marriott Larson has served as our Chief Operating Officer since July 2018 and as our President since October 2019. She was previously Senior Vice President, Executive Committee member, and Compliance Committee member at Achaogen, a publicly traded biopharmaceutical company that discovered, developed and commercialized treatments for infectious disease from May 2016 to June 2018, where she led Achaogen’s technical operations team—accountable for process development, supply chain and diagnostic development. Prior to Achaogen, she was Global Head of Technical Development Business Operations at Roche from October 2014 to April 2016, where she was responsible for business and technology infrastructure.

She spent a total of 20 years at Genentech/Roche in technical operations roles that included Automation Engineer, Associate Director Manufacturing Sciences, Director Process Development Engineering and Senior Director Technical Development Operations & Engineering. She has both deep technical expertise in scale-up of biopharmaceutical production and managing technical and operational organizations.

Ms. Larson was recognized by the Healthcare Business Women’s Association as a Rising Star in 2012, was recognized by Utah Business magazine as CXO of the Year in 2020, and was a 2019 Women Tech Council Awards winner. She has served on the advisory board of Colorado State University’s College of Engineering since 2015 and was recognized in 2019 as a CSU Distinguished Alumni. Ms. Larson received a B.S. in Chemical Engineering from Colorado State University.

What is Tina Marriott Larson's net worth?: The estimated net worth of Tina Marriott Larson is at least $3.37 million as of January 25th, 2024. Ms. Larson owns 414,548 shares of Recursion Pharmaceuticals stock worth more than $3,366,130 as of April 26th. This net worth evaluation does not reflect any other investments that Ms. Larson may own. Additionally, Ms. Larson receives an annual salary of $612,690.00 as COO at Recursion Pharmaceuticals. Learn More about Tina Marriott Larson's net worth.
How old is Tina Marriott Larson?: Ms. Larson is currently 49 years old. There are 4 older executives and no younger executives at Recursion Pharmaceuticals. Learn More on Tina Marriott Larson's age.
What is Tina Marriott Larson's salary?: As the COO of Recursion Pharmaceuticals, Inc., Ms. Larson earns $612,690.00 per year. The highest earning executive at Recursion Pharmaceuticals is Dr. Christopher C. Gibson Ph.D., Co-Founder, CEO & Director, who commands a salary of $695,180.00 per year. Learn More on Tina Marriott Larson's salary.
How do I contact Tina Marriott Larson?: The corporate mailing address for Ms. Larson and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Tina Marriott Larson's contact information.
Has Tina Marriott Larson been buying or selling shares of Recursion Pharmaceuticals?: Tina Marriott Larson has not been actively trading shares of Recursion Pharmaceuticals over the course of the past ninety days. Most recently, Tina Marriott Larson sold 8,000 shares of the business's stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $10.35, for a transaction totalling $82,800.00. Following the completion of the sale, the chief operating officer now directly owns 414,548 shares of the company's stock, valued at $4,290,571.80. Learn More on Tina Marriott Larson's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 70 times. They sold a total of 1,443,105 shares worth more than $13,646,266.83. The most recent insider tranaction occured on April, 17th when CFO Michael Secora sold 23,124 shares worth more than $175,279.92. Insiders at Recursion Pharmaceuticals own 20.0% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 4/17/2024.

Tina Marriott Larson Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/25/2024	Sell	8,000	$10.35	$82,800.00	414,548
11/16/2023	Sell	3,000	$6.76	$20,280.00	413,404
10/26/2023	Sell	3,000	$5.63	$16,890.00	418,782
9/28/2023	Sell	3,000	$7.72	$23,160.00	418,782
8/24/2023	Sell	3,000	$8.66	$25,980.00	418,782
7/27/2023	Sell	8,000	$13.62	$108,960.00	424,160
6/29/2023	Sell	3,000	$7.49	$22,470.00	424,160
5/31/2023	Sell	3,000	$8.63	$25,890.00	424,160
2/23/2023	Sell	8,000	$7.82	$62,560.00	427,844
1/26/2023	Sell	8,000	$8.07	$64,560.00	203,654
12/29/2022	Sell	8,000	$7.70	$61,600.00	203,654
11/17/2022	Sell	16,000	$10.96	$175,360.00	203,654
10/27/2022	Sell	16,000	$10.72	$171,520.00	205,107
9/29/2022	Sell	16,000	$10.86	$173,760.00	205,107
8/16/2022	Sell	16,000	$12.60	$201,600.00	295,107
12/16/2021	Sell	2,500	$18.74	$46,850.00
11/18/2021	Sell	2,500	$18.92	$47,300.00

Tina Marriott Larson Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $8.12

$7.68

$8.14

50 Day Range

MA: $10.37

$7.35

$15.52

2 Week Range

Now: $8.12

$4.54

$16.75

Volume

4,391,154 shs

Average Volume

6,494,168 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Tina Larson Biography and Net Worth

What is Tina Marriott Larson's net worth?

How old is Tina Marriott Larson?

What is Tina Marriott Larson's salary?

How do I contact Tina Marriott Larson?

Has Tina Marriott Larson been buying or selling shares of Recursion Pharmaceuticals?

Who are Recursion Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Recursion Pharmaceuticals?